Identification of high-risk disease using molecular profiling by Mymap
Highlights of ASH in CLL
John Gribben et al.
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy
The mechanisms driving relapse in multiple myeloma
The use of venetoclax (ABT-199) in the treatment of CLL